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Identification of potential synthetic lethal genes
to p53 using a computational biology approach
Xiaosheng Wang1* and Richard Simon2*
Abstract
Background: Identification of genes that are synthetic lethal to p53 is an important strategy for anticancer therapy
as p53 mutations have been reported to occur in more than half of all human cancer cases. Although genome-
wide RNAi screening is an effective approach to finding synthetic lethal genes, it is costly and labor-intensive.
Methods: To illustrate this approach, we identified potentially druggable genes synthetically lethal for p53 using
three microarray datasets for gene expression profiles of the NCI-60 cancer cell lines, one next-generation sequencing
(RNA-Seq) dataset from the Cancer Genome Atlas (TCGA) project, and one gene expression data from the Cancer Cell
Line Encyclopedia (CCLE) project. We selected the genes which encoded kinases and had significantly higher expression
in the tumors with functional p53 mutations (somatic mutations) than in the tumors without functional p53
mutations as the candidates of druggable synthetic lethal genes for p53. We identified important regulatory
networks and functional categories pertinent to these genes, and performed an extensive survey of literature to
find experimental evidence that support the synthetic lethality relationships between the genes identified
and p53. We also examined the drug sensitivity difference between NCI-60 cell lines with functional p53
mutations and NCI-60 cell lines without functional p53 mutations for the compounds that target the kinases
encoded by the genes identified.
Results: Our results indicated that some of the candidate genes we identified had been experimentally
verified to be synthetic lethal for p53 and promising targets for anticancer therapy while some other genes
were putative targets for development of cancer therapeutic agents.
Conclusions: Our study indicated that pre-screening of potential synthetic lethal genes using gene expression
profiles is a promising approach for improving the efficiency of synthetic lethal RNAi screening.
Keywords: Cancer, p53 mutations, Synthetic lethal genes, Gene expression profiles, Computational biology
Background
Because mutations in the p53 tumor suppressor gene have
been reported to occur in more than half of all human
cancer cases [1], anticancer drugs targeting p53 mutant
tumor cells are potentially efficacious for a large number
of patients with cancer. Whereas p53 mutations are not
directly druggable, its synthetic lethal partners may include
direct drug targets. Two genes are synthetic lethal if dis-
regulation of either alone doesn’t result in cell death but
dis-regulation of both leads to death of cells [2]. Thus, ab-
rogation of a gene that is synthetic lethal to p53 should
selectively kill p53-mutant cancer cells and spare normal
cells without p53 mutations. Based on this conceptual
framework, protein products of the genes that are syn-
thetic lethal to p53 mutations provide promising drug tar-
gets. Therefore, identification of genes synthetic lethal to
p53 mutations is a viable strategy for anticancer drug de-
velopment. The standard method for identifying synthetic
lethal genes is based on genome-wide or kinome-wide
RNAi screening which has been extensively utilized to
identify sensitizing targets to chemotherapeutic agents [3].
However, large-scale synthetic lethal RNAi screening strat-
egy is costly and labor-intensive. It is often restricted to
the examination of a single exposure time and a single
dose with few replicates, which may increase the false
negative rates of the assay [4]. An alternative proposal for
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identifying synthetic lethal genes compares the gene ex-
pression profiles of isogenically paired cell lines (tumor
suppressor genes mutant versus wild type), and identifies
differentially expressed genes between the two cell lines.
Then a gene-silencing by siRNA is performed on the dif-
ferentially expressed genes to examine their synthetic le-
thality to the tumor suppressor gene [4]. Obviously, the
gene expression profiles based method is cost-saving and
potentially efficient in identification of synthetic lethal
genes. Some investigators have used the method to find
synthetic lethal genes [5,6].
In the present study, we identified candidate synthetic
lethal genes to p53 using gene expression profiles. The
kinase-encoding genes which had higher expression in
the tumors with functional p53 mutations than in the
tumors without functional p53 mutations (non-func-
tional p53 mutations plus p53 wild-type) were regarded
as the candidates of druggable synthetic lethal genes to
p53. For purposes of the analyses here, we consider p53
nonsense (stop codon), frameshift and missense mutations
as functional p53 mutations, and p53 silent mutations as
non-functional p53 mutations. The silent mutations in-
clude synonymous mutations and mutations affecting
noncoding DNA. Further, we identified important regula-
tory networks and functional categories pertinent to the
candidate p53 synthetic lethal genes. We also performed
an extensive examination of literature to evaluate other
evidence for the putative synthetic lethality relationships
between the identified genes and p53. In addition, we ex-
amined the drug sensitivity differences between NCI-60
cell lines with functional p53 mutations and NCI-60 cell
lines without functional p53 mutations for the compounds
that target the kinases encoded by the genes identified.
Methods
Identification of candidates of druggable synthetic lethal
genes to p53
We first identified differentially expressed genes between
the tumors with functional p53 mutations and the tu-
mors without functional p53 mutations using the univar-
iate F-test or t-test at a two-sided significance level of
0.05. We also performed univariate permutation tests
with 10,000 permutations of the class label (functional
p53 mutation or not) to measure the significance of indi-
vidual genes. The proportion of the permutations that
gave a t-test or F-test p value as small as obtained with the
true class labels was the univariate permutation p value
for that gene. We also reported the false discovery rate for
each gene identified. The false discovery rate was esti-
mated using the method of Benjami and Hochberg [7].
This procedure was implemented with the class compari-
son between groups of arrays tool in BRB-ArrayTools, an
integrated package developed by Simon et al. for the
visualization and statistical analysis of gene expression
data [8]. The software can be freely downloaded from
the website: http://linus.nci.nih.gov/BRB-ArrayTools.
html. We selected the genes which showed higher relative
expression in the tumors with functional p53 mutations
and encode kinases from the differentially expressed gene
list as the candidates of druggable synthetic lethal genes
for p53.
Functional annotation for the candidate genes
We inferred significant networks and biological func-
tions associated with the candidate p53 synthetic lethal
genes using Ingenuity Pathway Analysis tool (IPA, In-
genuity® Systems, www.ingenuity.com). IPA is a system
that yields a set of networks relevant to a list of genes
based on the preserved records contained in the Ingenu-
ity Pathways Knowledge Base (IPKB).
Comparison of drug sensitivity between two groups of
cell lines
We compared drug sensitivity (GI50) between the cell
lines with functional p53 mutations and the cell lines
without functional p53 mutations using t-test statistics
(one-sided, the hypothesis of higher sensitivity in cell
lines with functional p53 mutations). GI50 is the con-
centration required to inhibit growth of cancer cell lines
by 50%. The lower GI50 value means higher drug sensi-
tivity. We obtained the normalized negative log(GI50)
values (z-score) for more than twenty thousands of com-
pounds from the CellMiner database [9,10].
Materials
We selected five gene expression datasets to perform
computational analysis. The five datasets include three
mRNA expression datasets of NCI-60 cancer cell lines,
one mRNA expression dataset of glioblastoma multiforme
(GBM) from the Cancer Genome Atlas (TCGA) project,
and one mRNA expression dataset of cancer cell lines
from the Cancer Cell Line Encyclopedia (CCLE) project,
which can be downloaded from the Developmental Thera-
peutics Program NCI/NIH website: http://dtp.nci.nih.gov/
mtargets/download.html, the Cancer Genome Atlas web-
site: http://tcga-data.nci.nih.gov/tcga/, and the Cancer Cell
Line Encyclopedia website: http://www.broadinstitute.org/
ccle/data/browseData?conversationPropagation=begin, re-
spectively. We obtained the p53 mutation data of NCI-60
cancer cell lines from the Wellcome Trust Sanger Institute
Cancer Genome Project website: http://www.sanger.ac.uk/
genetics/CGP/NCI60/. Table 1 is a summary of the five
gene expression datasets. The p53 mutation information
for the NCI-60 cancer cell lines, the TCGA tumor samples
and the CCLE cancer cell lines is provided in the supple-
mentary Additional file 1: Table S1.
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Results
Candidates of druggable synthetic lethal genes to p53
We identified 8, 2, 21, 50 and 36 gene candidates for syn-
thetic lethality to p53 for the NCI-60 Dataset 1, 2, 3,
TCGA Dataset, and CCLE Dataset respectively. Among
them, PLK1 was identified in four different datasets, and
CDK16, RYK, MTOR, STK17B, PLK4, MAST2, MAP3K4,
MARK2, CDK1, NEK2, PRKCSH, AURKA, BUB1, CDC7,
SRPK1, TTK and VRK1 were identified in two different
datasets. Table 2 lists these genes accompanying with
references related to them. The complete gene list (98
genes), and the genes identified in respective datasets
are presented in the supplementary Additional file 2:
Table S2. Experimental evidences have shown that many
of our identified genes have interactions with p53. For ex-
ample, in Table 2, a very interesting gene identified as syn-
thetic lethal to p53 is PLK1 which has been found to have
higher expression level in tumors with functional p53 mu-
tations than in tumors without functional p53 mutations
in four of the five datasets. Experimental evidence has
shown that proto-oncogene PLK1 is involved in p53 re-
lated pathways in that PLK1 inhibits transactivation and
pro-apoptotic functions of p53 function by physical
interaction and phosphorylation [11]. Interestingly, it
has been found that PLK1 expression is upregulated in
the case of Retinoblastoma tumor suppressor (RB) in-
activation, suggesting that PLK1 may be also a target
of the RB pathway [12].
MTOR is a serine/threonine protein kinase that regu-
lates cell growth, cell proliferation, cell motility, cell sur-
vival, protein synthesis, and transcription [23]. It has been
demonstrated that activation of p53 inhibits MTOR acti-
vity and regulates its downstream targets [24], consistent
with our finding that inactivation of p53 resulted in
upregulation of MTOR. Experimental evidence also re-
vealed that p53 and MTOR can collaboratively regulate
cell growth, proliferation, and death [22].
PLK4 regulates centriole duplication during the cell
cycle [41]. It has been shown that p53 and SAPK (stress-
activated protein kinase) pathways cooperatively regulate
PLK4 activity, and inactivation of both p53 and MKK4
genes result in hyperactivation of PLK4 which often
causes supernumerary centrosomes as frequently found
in cancer cells [26]. NEK2 encodes a serine/threonine-
protein kinase that is involved in mitotic regulation.
Evidence has shown that the gene is transcriptionally
repressed by p53 [42]. AURKA encodes a kinase that
Table 1 Summary of the five gene expression datasets
Dataset # Genes Class g # Samples h
NCI-60 Dataset 1 a 1092 f c1 / c2 60 (41/19)
NCI-60 Dataset 2 b 2266 f c1 / c2 60 (41/19)
NCI-60 Dataset 3 c 12625 c1 / c2 59 (40/19)
TCGA Dataset d 11861 c1 / c2 136 (47/89)
CCLE Dataset e 18988 c1 / c2 1036 (541/495)
a Affymetrix HUM6000 array data from Millenium Pharmaceuticals.
b cDNA array data from the Weinstein (NCI) and Brown & Botstein
(Stanford) groups.
c Affymetrix U95A data from Novartis.
d Gene expression data (RNA-Seq) for glioblastoma multiforme (GBM).
e mRNA expression data for cancer cell lines (Affymetrix U133+2 arrays).
f Number of genes filtered by excluding the genes with missing expression in
at least one sample.
g c1: functional p53 mutation; c2: non-functional p53 mutation or
p53 wild-type.
h The sample size of each class is given in parenthesis.
Table 2 The candidate genes with synthetic lethality to
p53 identified in at least two different datasets
Symbol Name Function Reference
PLK1 polo-like kinase 1 cell cycle regulation [13-19]
CDK16 cyclin-dependent
kinase 16
cell cycle regulation [20]
RYK receptor-like
tyrosine kinase
cellular growth and
differentiation
Regulation
[21]
MTOR mechanistic target
of rapamycin
(serine/threonine
kinase)
cellular metabolism,
growth, and proliferation
Regulation
[22-24]
STK17B serine/threonine
kinase 17b
positive regulation of
apoptosis
[25]
PLK4 polo-like kinase 4 cell cycle regulation [17,26]
MAST2 microtubule
associated serine/
threonine kinase 2
cellular growth and
differentiation
Regulation
[27]
MAP3K4 mitogen-activated
protein kinase
kinase kinase 4
role in signal
transduction cascades
[28]
MARK2 MAP/microtubule
affinity-regulating
kinase 2
cell polarity and
microtubule dynamics
regulation
[29]
CDK1 cyclin-dependent
kinase 1
cell cycle regulation [13,15-17,30,31]
NEK2 NIMA (never in
mitosis gene a)-
related kinase 2
cell cycle regulation [14-16,30]
PRKCSH protein kinase C
substrate 80K-H
roles in inflammation,
cell growth, signaling
and death
[32]
AURKA aurora kinase A cell cycle regulation [33,34]
BUB1 mitotic checkpoint
serine/threonine
kinase
cell cycle regulation [35]
CDC7 cell division cycle
7 homolog
(S. cerevisiae)
cell cycle regulation [30]
SRPK1 SRSF protein
kinase 1
cellular growth and
differentiation
Regulation
[36]
TTK TTK protein kinase cell cycle regulation [14-16,37,38]
VRK1 vaccinia related
kinase 1
cell cycle regulation [39,40]
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regulates cell cycle by involved in microtubule forma-
tion and/or stabilization at the spindle pole during
chromosome segregation. The interaction between p53
and AURKA has been investigated [33,34]. BUB1 en-
codes a kinase involved in mitotic spindle checkpoint
function. Mutation or aberrant BUB1 expression is as-
sociated with chromosomal instability, aneuploidy, and
human cancer [43]. It has been reported that p53 binds
BUB1 and monitors BUB1 function [35]. CDC7 en-
codes a protein kinase that is predominantly localized
in the nucleus. It has been found that a high correl-
ation between p53 loss and increased CDC7 expression
in primary breast cancers and in the cancer cell lines
[44]. An experimental study has proved its synthetic
lethality with p53 [45]. TTK encodes a dual specificity
protein kinase with the ability to phosphorylate tyrosine,
serine and threonine, and is critical for chromosome
alignment at the centromere during mitosis. It has been
shown that TTK interacts with p53 through mediating the
p53-dependent postmitotic checkpoint by phosphorylating
p53 [38]. VRK1 encodes a member of the vaccinia-related
kinase family of serine/threonine protein kinases which
localize to the nucleus and promote the stability of tran-
scriptionally active p53 molecules. The gene may regulate
cell proliferation by interaction with p53 [39,40].
To summarize, a large portion of the genes in Table 2
have experimental evidences of their interactions with
p53. Some of the other identified genes not present in
Table 2 like BRD2, have been experimentally verified to
be synthetic lethal to p53 [46].
Functional analysis of the genes identified
Network analysis of the gene set made up of p53 and its
98 candidate synthetic lethal genes identified using IPA
shows that the top network is associated with post-
translational modification and cancer (Figure 1). Figure 1
Figure 1 Top scoring network associated with p53 and its 98 candidate synthetic lethal genes. The p53-centered module is highlighted.
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shows that the network is p53-centered and many genes
are its direct regulatory targets. Interestingly, half of the
genes (PLK1, CDK1, NEK2, RYK, MAP3K4, BUB1,
CDC7, TTK, and VRK1) presented in Table 2 are directly
regulated by p53 (Figure 1), indicative of the relatedness of
our identified genes to p53. Biological function analysis
shows that the candidate synthetic lethal genes to p53 are
mostly relevant to post-translational modification, cell
cycle, cell development, cancer etc. (p-value<10-8, Figure 2).
Table 3 presents 11 significant biological functions associ-
ated with the candidate synthetic lethal genes to p53.
Many identified genes are involved in cell cycle
regulation
The repression activity of its target genes involved in the
cell cycle enables p53 to control cell proliferation by in-
ducing cell cycle arrest. Consequently, these target genes
are anticipated to show higher relative expression in
functional p53 mutants and that is observed in our re-
sults. Table 2 and Table 3 show that a large portion of
identified genes are involved in the cell cycle regulation
which include CDK1, CHEK2, TTK, BUB1B, CDC7,
PLK1, PLK4, CDK11A, AURKA, VRK1, MTOR, NEK2
etc. Among them, CDK1 encodes the protein which is
a member of the Ser/Thr protein kinase family, and is
critical for cell cycle G1/S and G2/M phase transitions.
Accumulated evidence has shown that this gene is a
target of p53 transcriptional repression and had elevated
expression in p53 loss/mutation status [15,16,30,31,47].
Oncogenic properties of PLK1 have been believed to be
due to its role in driving cell cycle progression. In fact,
PLK1 is an early trigger for G2/M transition and supports
the functional maturation of the centrosome in late G2/
early prophase. Its expression reaches peak during G2/M
phase. CDC7 encodes a cell division cycle protein kinase
that is involved in regulation of the cell cycle at the point
of chromosmal DNA replication, and is specifically critical
for the G1/S transition [48].
Mitosis is one of the most dramatic stages during the cell
cycle. Any errors in this process often lead to aneuploidy,
genomic instability, and tumorigenesis. The regulation of
mitosis relies significantly on the protein phosphorylation
of mitotic kinases. The important mitotic kinases include
several families of kinases: CDK, POLO, AURORA and
NIMA, and the mitotic checkpoint kinases [49]. Table 4
lists the identified genes that encode mitotic kinases and
are classified based on the aforementioned categories. In-
creasing evidence suggests that p53 regulates the expres-
sion and function of many mitotic kinases and multiple
mitotic kinases can also be involved in p53-mediated
signaling by phosphorylation of p53, suggesting active
interactions between p53 and mitotic kinases in the
cell cycle regulation [50]. Our results lent a support
for the argument.
It has been shown that the mitogen-activated protein
kinase (MAPK) signaling pathways play important
roles in control of the eukaryotic cell cycle, and the
control of cell cycle progression by MAPK pathways is
Figure 2 Important biological functions associated with the candidate p53 synthetic lethal genes.
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p53 dependent [51-54]. We have identified a group of
MAPK pathways related genes that are potentially syn-
thetic lethal to p53. These genes include RAF1, MAP3K13,
MAP3K15, MAP3K4, MAP3K7, MAP3K9, MAP4K5,
MAPK13, MAPK14, MAPKAPK5 etc.
Besides, many other genes such as CHKA, STK17B,
RYK and VRK1 also play a significant role in regulation
of cell cycle and proliferation.
Some genes have been identified as potential targets of
anticancer agents
Some of the identified genes such as PLK1, CDC7, MTOR,
CHKA, TTK and RAF1 have been active or putative anti-
cancer therapeutic targets. PLK1 has been recognized as a
promising target for cancer therapy for its essential role in
mitosis [15,18,19]. Our computational analysis has indi-
cated that PLK1 is likely to be synthetic lethal with p53 as
can been verified by two experimental studies. One study
has shown that p53-deficient tumors have higher sensitivity
towards the PLK1 inhibitor GSK461364A [55]. Another
study has revealed that cell lines harboring p53 mutations
are more sensitive to PLK1 inhibitors [56]. So far, some
PLK1 inhibitors have demonstrated encouraging results in
phase 1 or 2 clinical trials of cancer treatment. Table 5 lists
some PLK1 inhibitors used for clinical trials. Interestingly,
PLK1 has been found to have synthetic lethal interaction
with KRAS [12]. Since many colon cancer [57], pancreatic
cancer [58] and lung cancers [59] are associated with
KRAS mutations, development of drugs targeting PLK1
kinase could be promising in treatment of these cancers.
CDC7 has been suggested to be a promising target
for the development of anticancer kinase inhibitors
[45]. An experimental study has indicated that deve-
lopment of CDC7 kinase inhibitors may be efficacious
in treatment of the aggressive p53-mutant breast can-
cer subtypes [60].
Many cancers occur due to disregulation of MTOR
signaling, and therefore development of MTOR inhibi-
tors has been an active field in cancer research [61,62].
Some MTOR inhibitors (e.g. rapamycin, everolimus) are
beginning to be used in the treatment of cancer. Some
others like rapalogs, ridaforolimus and BGT226 are cur-
rently in clinical development.
AURKA have been attractive targets for cancer treat-
ment during past several years. Several ongoing clinical
trials are assessing the anticancer efficacy of AURKA in-
hibitors [63]. We have identified several members of
protein kinase C (PKC) gene family including PRKCH,
PRKCI, PRKCSH, and PRKCZ. PKC isozymes are becom-
ing attractive targets for therapeutic intervention because
of their many cellular roles [64,65]. CHKA is an enzyme
involved in the metabolism of phospholipids which has
been found to play a role in the regulation of cell prolifera-
tion, oncogenic transformation and human carcinogen-
esis, and has been ascertained as a promising target for
cancer therapy [66-69]. One study has demonstrated that
inactivation of TTK inhibited cancer cell growth in vitro,
suggesting that targeting the gene might be an effective
anticancer strategy [37]. RAF1 encodes a MAP kinase
Table 4 The identified genes encoding mitotic kinases
Category i Gene
CDK Family CDK1, CDK2, CDK9, CDK11A, CDK11B, CDK19
POLO Family PLK1, PLK4
AURORA Family AURKA
NIMA Family NEK2
mitotic checkpoint BUB1,TTK
i Some kinases regulating mitosis may not be presented in the table such as
MAP kinases.
Table 3 Important biological functions relevant to the
genes identified
Category # Molecules Representative genes
Post-Translational
Modification
65 RAF1,SRPK1,EPHB2,PHKG2,MARK1,
MELK,MAPK13,CDK9, SRPK2,PLK4,
STK17B,EIF2AK1,CHKA,RPS6KB1,
MAP3K9
Cell Cycle 42 CDK1,NEK2,PIK3CA,SRPK1,CDC7,
CDK11A,CDK11B,MELK, CDK9,TTK,
BRAF, SRPK2,PLK4,MTOR,CLK1
Cellular Development 57 BRAF,EPHB2,CDC7,MAP3K4,MAPK13,
CDK9,RIPK2,CDK16, GNE,EIF2AK1,
RPS6KB1,EPHA1,AURKA,CHKA,SIK1
Cellular Growth and
Proliferation
62 MTOR,EPHB2,CDC7,MELK,MAPK13,
CDK9,SRPK2,PLK4, RIPK2,STK17B,
EIF2AK1,GNE,NEK2,RPS6KB1,EPHA1
Cell Death and
Survival
61 TTK,SRPK1,EPHB2,CDC7,MELK,
MAPK13,MAP3K4,CDK9, SRPK2,PLK4,
RIPK2,STK17B,GNE,EIF2AK1,MTOR
Cell Signaling 28 PLK1,SRPK1,MARK2,MARK1,MAPK13,
MAP3K4,PRKCZ, IRAK1,BRAF,SRPK2,
ROR2,MTOR,NEK2,CLK1,MAP3K7
Amino Acid
Metabolism
15 SRPK1,EPHB2,EPHA1,ACVR1,TTK,
CDK9,PHKA2,MTOR,CLK1,ABL2,
PDGFRA,TLK2,CHEK2,C8orf44-SGK3/
SGK3
Small Molecule
Biochemistry
29 MAST2,PIK3CA,SRPK1,EPHB2,CDK16,
MARK2,TTK,CDK9, PRKCZ,PHKA2,
MTOR,HK2,CLK1,NTRK1,PDGFRA
Cellular Assembly and
Organization
45 CHEK2,PIK3CA,SRPK1,EPHB2,MARK2,
CDC7,MARK1,STK35,TTK,PRKCZ,
PRKCSH,BRAF,ROR2,PLK4,MTOR
DNA Replication,
Recombination,
and Repair
26 ERBB3,PIK3CA,SRPK1,CDC7,TTK,
PRKCZ,BRAF,PLK4,MTOR,NEK2,NTRK1,
PDGFRA,SPHK1,CHEK2,PLK1
Cancer 64 TTK,SRPK1,EPHB2,CDC7,MARK1,
MELK,MAP3K4,MAPK13,STK35,SCYL2,
SRPK2,PLK4,STK17B,SCYL3,EIF2AK1
Cellular Function
and Maintenance
43 PIK3CA,EPHB2,MARK2,MARK1,
MAPK13,CDK9,TTK,STK35,PRKCZ,
PRKCSH,BRAF,ROR2,PLK4,MTOR,PLK1
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kinase kinase (MAP3K), and is an excellent molecular
target for anticancer therapy because of its important
role in the control of gene expression involved in the
cell division cycle, apoptosis, cell differentiation and
cell migration [70].
Table 5 shows a partial list of clinically approved or ex-
perimentally active compounds that target some genes we
have identified. For genes MTOR, PDGFRA, CHKA, and
RAF1, there have been clinically approved compounds to
target them, while for some other genes such as PLK1,
CDC7, AURKA, STK38 and CDK1, there exist experi-
mentally active compounds to target them (Table 5).
In-vitro sensitivity of cell lines to compounds that target
the identified p53 synthetic lethal genes
For 16 compounds with GI50 values available in Table 5,
we compared their drug sensitivities between the NCI60
cell lines with functional p53 mutations and the NCI60
cell lines without functional p53 mutations. We found
that there were ten compounds showing higher drug
sensitivity in the cell lines with functional p53 mutations
than in the cell lines without functional p53 mutations
(Table 6). Few of the differences were statistically sig-
nificant but the statistical power of the comparison
was limited by the number of cell lines with functional
p53 mutations. The compound paclitaxel has the
smallest p-value, and exhibits inhibitory activity on
three different kinases: PLK1, AURKA, and BUB1.
There are six compounds whose means of drug sensi-
tivity are slightly lower in the NCI60 cell lines with
Table 5 Approved or experimental compounds that
target related genes
Gene symbol Drug & compound name j Status
PLK1 DB08059, DB07789, DB06963,
DB06897, DB07186, BI 2536,
cyclapolin 9, GW843682X, ADP,
threonine, serine, pyridoxal,
nocodazole, paclitaxel,
phosphoserine, TAK-960
experimental
CDC7 PHA 767491 hydrochloride, BMS-
863233, NMS-1116354
experimental
CDK1 flavopiridol, hymenialdisine,
indirubin-3′-monoxime,
olomoucine, SU9516
experimental
MTOR rapamycin, everolimus approved
CDK16 DB07766 experimental
PLK4 ADP, microplasmin, serine,
fibrinogen, cysteine
experimental
STK17B quercetin experimental
TTK DB01782 experimental
STK38 mercaptopurine experimental
NEK2 DB07180 experimental
AURKA Adenosine-5′-Diphosphate,
phosphonothreonine, taxane,
paclitaxel, serine, threonine
experimental
BUB1 cytosine, paclitaxel, nocodazole experimental
SRPK1 gemcitabine, cisplatin, serine,
arginine
experimental
PRKCSH VU 0155069, cellobiose experimental
PKC family (PRKCH,
PRKCI, PRKCSH,
PRKCZ)
bryostatin, aprinocarsen,
enzastaurin, tamoxifen citrate,
midostaurin, UCN-01
experimental
MARK2 glycogen experimental
PDGFRA imatinib, sorafenib, sunitinib,
pazopanib, axitinib
approved
BRD2 PFI 1, sulfadiazine, dihydrofolate experimental
CHEK2 DDUG experimental
CERK NVP 231 experimental
UCK2 DB03431, DB04272, DB02097,
DB03403, DB02431, DB04005
experimental
AK2 DB01717 experimental
CHKA choline approved
RAF1 sorafenib approved
CSNK2B TMCB, TBB, ellagic acid experimental
j Gene-related drug compounds identified according to DrugBank, PharmGKB,
Tocris Bioscience, HMDB, and/or Novoseek; The data were obtained from the
website: http://www.genecards.org and http://www.cancer.gov/drugdictionary.
Table 6 Comparison of drug sensitivity between two
groups of cell lines
Compound Mean of drug
sensitivity k
p-value n Targets
c1 l c2 m
paclitaxel 0.1366 -0.2790 0.0323 PLK1, AURKA, BUB1
hymenialdisine 0.0590 -0.1359 0.2529 CDK1
olomoucine 0.0665 -0.1405 0.2311 CDK1
mercaptopurine 0.1012 -0.2037 0.1134 STK38
tamoxifen citrate 0.1003 -0.2121 0.0976 PRKCH, PRKCI, PRKCZ
imatinib 0.0425 -0.0358 0.3791 PDGFRA
sunitinib 0.0243 -0.0132 0.4384 PDGFRA
sorafenib 0.0801 -0.1779 0.184 PDGFRA, RAF1
DDUG 0.0860 -0.1811 0.1218 CHEK2
choline 0.0390 -0.2779 0.1188 CHKA
rapamycin -0.1044 0.1784 0.8866 MTOR
everolimus 0.0095 0.1526 0.7188 MTOR
nocodazole -0.0636 0.0026 0.5937 PLK1, BUB1
cisplatin -0.1546 0.1984 0.9376 SRPK1
bryostatin -0.0218 0.0958 0.6602 PKC family
axitinib -0.0278 0.0589 0.6235 PDGFRA
k mean of standardized negative log(GI50) values (higher means indicate
higher sensitivity).
l c1: The NCI60 cell lines with functional p53 mutations.
m c2: The NCI60 cell lines with non-functional p53 mutations or p53 wild-type.
n The one-sided t-test statistics (hypothesis of higher drug sensitivity in cell
lines with functional p53 mutations).
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functional p53 mutations, but don’t show statistically
significant difference (Table 6).
Discussion
A wealth of studies have established that about half of
human cancer cases harbor p53 mutations, about 80% of
which are missense mutations [71]. Therefore, cancer
therapeutic strategies that focus on cells harboring p53
mutations are needed. Because tumor suppressor genes
such as p53 are not druggable, it is rational to develop
anticancer agents for druggable genes which have syn-
thetic lethal interaction with p53. Although the genome-
wide synthetic lethal RNAi screening strategy has been
demonstrated to be effective in identifying potential targets
for cancer therapeutic agents, pre-filtering of synthetic le-
thal gene candidates by the computational approach could
enhance the efficiency of synthetic lethal RNAi screening.
In the present study, we tried to evaluate this approach for
identifying synthetic lethal p53 candidate genes using gene
expression data. The results are generally promising as
many of the identified genes have been experimentally veri-
fied to be synthetic lethal with or interacted with p53, and
some of them have been suggested to be potential targets
for anticancer therapy (see Table 2, Table 5 and Additional
file 2: Table S2). More importantly, the p53 synthetic lethal
genes we identified all encode protein kinases which have
been targeted for the discovery of small molecule inhibitors
as potential anticancer agents.
An important cluster of genes identified was involved
in regulation of the cell cycle, in accordance with the
pivotal role of p53 in cell cycle checkpoints [46,72,73].
Because p53 is a key regulator of G1/S checkpoints, and
can promote cell cycle arrest or apoptosis in response to
DNA damage, cancer cells with p53 mutations often
have defects in the G1/S checkpoint while keep normal
function in the G2/M checkpoint. As a result, abroga-
tion of the G2/M checkpoint would be effective in pro-
moting cell cycle arrest or apoptosis of p53-mutant
cancer cells in the G2/M checkpoint which have escaped
the fate of cell cycle arrest or apoptosis in the G1/M
checkpoint. Therefore, the inhibition of G2/M checkpoint
related genes should sensitize p53-mutant cancer cells to
anticancer therapy while sparing normal cells [74]. Actu-
ally, among the p53 synthetic lethal gene candidates we
identified, many are involved in regulation of G2/M
checkpoint. A particularly interesting class of genes is the
centrosome-associated regulator of the G2/M checkpoint
such as PLK1, PLK4, CDK1, AURKA, and NEK2. In fact,
centrosome has been found to play an important role in
G2/M checkpoint function in that a growing number of
G2/M checkpoint regulators have been found in the
centrosome [75].
p53 functions are ultimately mediated by activation
and repression of target genes. Wild-type p53 can induce
growth arrest or apoptosis in response to stress signals
such as DNA damage, UV radiation, hypoxia and chemo-
therapeutic agents by activation of genes which promote
apoptosis or growth arrest while repression of genes in-
volved in cell cycle and proliferation [76]. The genes iden-
tified in our study mostly belong to the target genes
repressed by p53. The elevated expression of these genes
is largely attributable to loss of p53 repression activity di-
rectly or indirectly, whereas some genes possibly have no
connectivity with the p53 repression function at all.
As many cancer therapies tend to be less effective in
p53 mutant patients, the use of small molecule inhibi-
tors that target p53 synthetic lethal genes may enhance
chemotherapeutic efficacy for these patients. Among the
gene list in Table 2, in addition to the genes which have
been experimentally verified to be synthetic lethal with
p53 by RNAi screening, other genes are worth further
investigation using RNAi screening because all of them
encode druggable kinases.
Generally speaking, our gene expression profiles based
pre-screening of potential p53 synthetic lethal genes pro-
vides an approach to identifying candidate genes for
more extensive synthetic lethal RNAi screening, and
may be useful in some cases to supplement the standard
method.
Here we have used a relatively loose significance level
(p-value<0.05) to identify differentially expressed genes
when thousands or tens of thousands genes were tested.
We didn’t use more stringent cutoff mainly considering
that the number of kinase-encoding genes occupy a
small proportion in all genes, and a smaller cutoff may
filter out most of the kinase genes in the small-sample
datasets (NCI60 cell lines datasets). In fact, for the larger
datasets (TCGA and CCLE), most of the identified kinase
genes have very small p-values (see Additional file 2:
Table S2). If we restrict the analysis of differentially
expressed genes to kinase genes, the 0.05 of cutoff
would be more adequate as the number of tested genes
dramatically decreases. Because the FDR calculation
depends on the number of genes tested, we will have
many fewer tests to correct for and the FDR identified
in supplementary Additional file 2: Table S2 will de-
crease dramatically.
It should be noted that gene expression differences
between the tumors with functional p53 mutations and
the tumors without functional p53 mutations do not es-
tablish synthetic lethal relationships between differen-
tially expressed genes and p53. RNAi screen provides a
more direct way of establishing synthetic lethality rela-
tionships. Moreover, gene expression differences may
not be a result of altered p53 mutation status. Some in-
direct or unrelated effects may exist. For example, some
other genes (or pathways) other than p53 may influence
the expression of the genes identified. In the present
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study, we have only identified candidate p53 synthetic le-
thal genes. The reliability of the results should be vali-
dated by RNAi screening or in-vivo experiments. Direct
validation by in-vivo experiments using available kinase
inhibitors may in some cases be the most direct ap-
proach since synthetic lethality screening itself needs
such validation because of off-target effects.
An alternative approach to treating the p53-mutant tu-
mors is to restore p53 tumor-suppressive function [77].
However, this is a more challenging field in that it is
more difficult to develop a drug that reactivates the
function of an inactivated gene than to develop a drug
that inhibits the function of a hyperactivated gene, al-
though reconstitution of the p53 pathway is believed to
be an exciting novel therapeutic challenge for cancer
therapeutics [78-83].
Conclusion
Pre-screening of potential synthetic lethal genes using
gene expression profiles is a promising approach for im-
proving the efficiency of synthetic lethal RNAi screening,
and may supplement the standard method in some
cases. However, the reliability of the method should be
validated by RNAi screening or in-vivo experiments.
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